These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 20520852)
21. Pharmacological evaluation of the long-term effects of xanomeline on the M(1) muscarinic acetylcholine receptor. Grant MK; Noetzel MJ; De Lorme KC; Jakubík J; Doležal V; El-Fakahany EE PLoS One; 2010 Dec; 5(12):e15722. PubMed ID: 21203415 [TBL] [Abstract][Full Text] [Related]
23. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia. Brannan SK; Sawchak S; Miller AC; Lieberman JA; Paul SM; Breier A N Engl J Med; 2021 Feb; 384(8):717-726. PubMed ID: 33626254 [TBL] [Abstract][Full Text] [Related]
24. Wash-resistantly bound xanomeline inhibits acetylcholine release by persistent activation of presynaptic M(2) and M(4) muscarinic receptors in rat brain. Machová E; Jakubík J; El-Fakahany EE; Dolezal V J Pharmacol Exp Ther; 2007 Jul; 322(1):316-23. PubMed ID: 17446301 [TBL] [Abstract][Full Text] [Related]
25. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders. Teal LB; Gould RW; Felts AS; Jones CK Adv Pharmacol; 2019; 86():153-196. PubMed ID: 31378251 [TBL] [Abstract][Full Text] [Related]
26. Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia. Dean B Curr Pharm Biotechnol; 2012 Jun; 13(8):1563-71. PubMed ID: 22283751 [TBL] [Abstract][Full Text] [Related]
27. Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors. Messer WS; Rajeswaran WG; Cao Y; Zhang HJ; el-Assadi AA; Dockery C; Liske J; O'Brien J; Williams FE; Huang XP; Wroblewski ME; Nagy PI; Peseckis SM Pharm Acta Helv; 2000 Mar; 74(2-3):135-40. PubMed ID: 10812950 [TBL] [Abstract][Full Text] [Related]
28. Biased Profile of Xanomeline at the Recombinant Human M McDonald JK; van der Westhuizen ET; Pham V; Thompson G; Felder CC; Paul SM; Thal DM; Christopoulos A; Valant C ACS Chem Neurosci; 2022 Apr; 13(8):1206-1218. PubMed ID: 35380782 [TBL] [Abstract][Full Text] [Related]
29. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. Jones CK; Brady AE; Davis AA; Xiang Z; Bubser M; Tantawy MN; Kane AS; Bridges TM; Kennedy JP; Bradley SR; Peterson TE; Ansari MS; Baldwin RM; Kessler RM; Deutch AY; Lah JJ; Levey AI; Lindsley CW; Conn PJ J Neurosci; 2008 Oct; 28(41):10422-33. PubMed ID: 18842902 [TBL] [Abstract][Full Text] [Related]
30. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Conn PJ; Jones CK; Lindsley CW Trends Pharmacol Sci; 2009 Mar; 30(3):148-55. PubMed ID: 19201489 [TBL] [Abstract][Full Text] [Related]
34. Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors. Jakubík J; El-Fakahany EE; Dolezal V Mol Pharmacol; 2006 Aug; 70(2):656-66. PubMed ID: 16675658 [TBL] [Abstract][Full Text] [Related]
35. Long-term changes in the muscarinic M1 receptor induced by instantaneous formation of wash-resistant xanomeline-receptor complex. De Lorme KC; Grant MK; Noetzel MJ; Polson SB; El-Fakahany EE J Pharmacol Exp Ther; 2007 Dec; 323(3):868-76. PubMed ID: 17855477 [TBL] [Abstract][Full Text] [Related]
37. Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment. Azargoonjahromi A Clin Drug Investig; 2024 Jul; 44(7):471-493. PubMed ID: 38904739 [TBL] [Abstract][Full Text] [Related]
38. Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline. Stengel PW; Cohen ML J Pharmacol Exp Ther; 2001 Mar; 296(3):818-24. PubMed ID: 11181912 [TBL] [Abstract][Full Text] [Related]
39. Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. Suratman S; Leach K; Sexton P; Felder C; Loiacono R; Christopoulos A Br J Pharmacol; 2011 Apr; 162(7):1659-70. PubMed ID: 21198541 [TBL] [Abstract][Full Text] [Related]
40. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Chan WY; McKinzie DL; Bose S; Mitchell SN; Witkin JM; Thompson RC; Christopoulos A; Lazareno S; Birdsall NJ; Bymaster FP; Felder CC Proc Natl Acad Sci U S A; 2008 Aug; 105(31):10978-83. PubMed ID: 18678919 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]